Peter Buehler is Valneva’s new chief financial officer | people | Professional life

Valneva SE, the specialty vaccine company focused on developing and marketing preventive vaccines against infectious diseases with significant unmet medical needs, today announced the appointment of Peter Buehler to the position of Chief Financial Officer and Member of the Board of Directors.

Buehler has more than 20 years of experience in the strategic and financial management of life sciences and technology companies. He is currently the CFO of Nasdaq-listed Swiss Diagnostics firm Quotient, where he has strengthened its balance sheet and raised nearly $200 million in cash. Prior to joining Quotient, he was Group Finance Director of Zaluvida AG and Group Finance Director of Stallergenes Greer Plc, managing a complex merger project for the merger of a French and American company.

Prior to that, Buehler held senior financial positions at Eli Lilly, Merck Serono and Logitech. He is a certified public accountant and holds an Executive MBA from SBS Swiss Business School. To ensure business continuity and transition, Valneva Acting Chief Financial Officer David Lawrence has agreed to support it through the end of 2021. Buehler is expected to move to Valneva within the next six months. Thomas Lingelbach, CEO of Valneva, said: “We are very pleased to have Bühler join us. With his proven experience in financial and strategic management, and above all his US/NASDAQ experience, he would be an excellent addition to our management team. I would also like to thank David for his continued commitment, commitment and significant contribution to his current transitional role as Deputy Chief Financial Officer.”

“I look forward to joining the Valneva Board of Directors and leading the financial organization to contribute to future success as the company advances to the next level in its strategy,” said Peter Bühler.

The company takes a highly specialized and focused approach to vaccine development, starting with identifying fatal and debilitating infectious diseases for which there is no preventive vaccine solution and for which there are limited treatment options. He then uses his deep understanding of vaccinology, including his expertise in multiple vaccine methods, as well as his well-established skills in vaccine development, to develop preventive vaccines against these diseases. The company has used its experience and skills to successfully commercialize two vaccines and rapidly acquire a wide range of vaccine candidates in and through the clinic, including candidates for Lyme disease, chikungunya virus and COVID-19. (red)